Ipilimumab, the first monoclonal antibody targeting CTLA-4 [87], has been the subject of extensive research involving 2901 patients across 25 clinical trials, demonstrating durable responses and prolonged survival in advanced melanoma cases. The gene discussed is CTLA4; the disease is melanoma.